P R Pharma Source Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 18-07-2024
- Paid Up Capital ₹ 5.00 M
as on 18-07-2024
- Company Age 17 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.80 Cr
as on 18-07-2024
- Revenue -17.63%
(FY 2023)
- Profit -55.10%
(FY 2023)
- Ebitda -50.14%
(FY 2023)
- Net Worth 8.17%
(FY 2023)
- Total Assets -37.15%
(FY 2023)
About P R Pharma Source
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹1.80 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Paresh Bagadia and Kaushik Mehta serve as directors at the Company.
- CIN/LLPIN
U52311MH2007PTC171721
- Company No.
171721
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jun 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does P R Pharma Source Private Limited offer?
P R Pharma Source Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API Intermediate, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Business Planning and Management, Business Consultant, Respiratory System Drugs, Anti Asthma Drug, Nervous System and Antipsychotic API, Cardiovascular Drugs & Medication.
Who are the key members and board of directors at P R Pharma Source?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Paresh Bagadia  | Managing Director | 16-Jun-2007 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kaushik Mehta | Additional Director | 06-Jul-2013 | Current |
Financial Performance of P R Pharma Source.
P R Pharma Source Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 17.63% decrease. The company also saw a substantial fall in profitability, with a 55.1% decrease in profit. The company's net worth moved up by a moderate rise of 8.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of P R Pharma Source?
In 2023, P R Pharma Source had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Spark Alchemy Private LimitedActive 12 years 1 month
Paresh Bagadia and Kaushik Mehta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 22 Jun 2016 | ₹3.00 M | Satisfied |
Standard Chartered Bank Creation Date: 25 Mar 2015 | ₹1.50 Cr | Satisfied |
How Many Employees Work at P R Pharma Source?
Unlock and access historical data on people associated with P R Pharma Source, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of P R Pharma Source, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped P R Pharma Source's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
